Analyst Price Targets — TWST
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 5, 2026 11:24 am | — | Piper Sandler | $115.00 | $99.45 | TheFly | Twist Bioscience price target raised to $115 from $85 at Piper Sandler |
| August 4, 2026 10:21 am | — | Robert W. Baird | $115.00 | $101.06 | TheFly | Twist Bioscience price target raised to $115 from $113 at Baird |
| July 16, 2026 10:13 am | Puneet Souda | Leerink Partners | $110.00 | $92.61 | TheFly | Twist Bioscience price target raised to $110 from $80 at Leerink |
| July 14, 2026 10:54 am | Kyle Mikson | Canaccord Genuity | $120.00 | $90.35 | TheFly | Twist Bioscience price target raised to $120 from $90 at Canaccord |
| July 6, 2026 12:01 pm | — | Evercore ISI | $102.00 | $97.95 | TheFly | Twist Bioscience downgraded to In Line from Outperform at Evercore ISI |
| June 29, 2026 11:01 am | — | Guggenheim | $107.00 | $99.84 | TheFly | Twist Bioscience price target raised to $107 from $60 at Guggenheim |
| June 24, 2026 8:51 am | Luke Sergott | Barclays | $95.00 | $85.00 | TheFly | Twist Bioscience price target raised to $95 from $65 at Barclays |
| June 15, 2026 11:44 am | — | Cowen & Co. | $89.00 | $76.17 | TheFly | Twist Bioscience price target raised to $89 from $68 at TD Cowen |
| June 15, 2026 9:43 am | — | Canaccord Genuity | $90.00 | $76.17 | TheFly | Twist Bioscience initiated with a Buy at Canaccord |
| June 15, 2026 9:32 am | — | UBS | $89.00 | $76.17 | StreetInsider | Twist Bioscience (TWST) PT Raised to $89 at TD Cowen |
Latest News for TWST
Brandywine Managers LLC acquired a new position in shares of Twist Bioscience Corporation (NASDAQ: TWST) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,970 shares of the company's stock, valued at approximately $2,157,000. Twist Bioscience comprises
Deutsche Bank AG acquired a new stake in Twist Bioscience Corporation (NASDAQ: TWST) in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 90,053 shares of the company's stock, valued at approximately $9,265,000. Deutsche Bank AG owned about 0.14% of Twist
Twist Bioscience Corporation is rated Hold, as its $9.5bn valuation appears disconnected from current fundamentals, and profitability remains elusive. TWST's recent 200% stock surge is driven by AI-related news, short squeeze dynamics, and strong DSPS revenue growth, not by blowout earnings. Full-year 2026 guidance was raised to $456–$457m revenue with adjusted EBITDA breakeven targeted, but losses and elevated SG&A…
Twist Bioscience Corp (NASDAQ:TWST) shares surged Wednesday after Anthropic named the company an independent evaluator in a new AI-driven protein design campaign.
Anthropic is preparing what could be the largest IPO of 2026, and it's telling investors the pitch goes well beyond chatbots. According to the Wall Street Journal, "Anthropic is targeting a public debut in September or early October, people familiar with its plans said." In those same meetings, the company told some investors that it... The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TWST.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.